

Dr Reddy's launches generic Zoledronic acid injection

05 March 2013 | News | By BioSpectrum Bureau

Dr. Reddy's launches a generic Zoledronic acid injection



Dr. Reddy's Laboratories has announced that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa (zoledronic acid) 4 mg/5 mL injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for the same. Zometa is a registered trademark of Novartis AG

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S.Africa, Romania, and New Zealand.